Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells

European Journal of Pharmacology

Volumn 755, Issue , 2015, Pages 42-49

  Pugazhenthi, Subbiah ^a,b   Qin, LiMei ^a   Bouchard, Ron ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

CREB and cells; Diabetes; Dipeptidyl peptidase 4; GLP 1; Insulin

Indexed keywords

ALOGLIPTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; MITOCHONDRIAL PROTEIN; PROTEIN BCL 2; PROTEIN BIRC3; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; BIRC3 PROTEIN, RAT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; INHIBITOR OF APOPTOSIS PROTEIN; INSULIN RECEPTOR SUBSTRATE; IRS3 PROTEIN, RAT; PIPERIDINE DERIVATIVE; TRIACYLGLYCEROL; URACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; IN VIVO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; BLOOD; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; METABOLISM; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; INHIBITOR OF APOPTOSIS PROTEINS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-SECRETING CELLS; MALE; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS, ZUCKER; TRIGLYCERIDES; URACIL;

EID: 84925004313     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.02.024     Document Type: Article

References (27)

1. A. Ashkenazi, and V.M. Dixit Death receptors: signaling and modulation Science 281 1998 1305 1308
2. R. Baetta, and A. Corsini Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 71 2011 1441 1467
3. A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, and P.C. Butler Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes Diabetes 52 2003 102 110
4. R.K. Campbell, and S. Miller New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy Diabetes Educ. 35 2009 731 747
5. R.A. DeFronzo, P.R. Fleck, C.A. Wilson, and Q. Mekki Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study Diabetes Care 31 2008 2315 2317
6. D.J. Drucker The biology of incretin hormones Cell Metab. 3 2006 153 165
7. J. Feng, Z. Zhang, M.B. Wallace, J.A. Stafford, S.W. Kaldor, D.B. Kassel, M. Navre, L. Shi, R.J. Skene, T. Asakawa, K. Takeuchi, R. Xu, D.R. Webb, and S.L. Gwaltney 2nd Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV J. Med. Chem. 50 2007 2297 2300
8. A. Inada, Y. Hamamoto, Y. Tsuura, J. Miyazaki, S. Toyokuni, Y. Ihara, K. Nagai, Y. Yamada, S. Bonner-Weir, and Y. Seino Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells Mol. Cell. Biol. 24 2004 2831 2841
9. P. Jambal, S. Masterson, A. Nesterova, R. Bouchard, B. Bergman, J.C. Hutton, L.M. Boxer, J.E. Reusch, and S. Pugazhenthi Cytokine-mediated downregulation of the transcription factor CREB in pancreatic beta -cells J. Biol. Chem. 278 2003 23055 23065
10. U.S. Jhala, G. Canettieri, R.A. Screaton, R.N. Kulkarni, S. Krajewski, J. Reed, J. Walker, X. Lin, M. White, and M. Montminy cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2 Genes Dev. 17 2003 1575 1580
11. S. Kawashima, T.A. Matsuoka, H. Kaneto, Y. Tochino, K. Kato, K. Yamamoto, T. Yamamoto, M. Matsuhisa, and I. Shimomura Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice Biochem. Biophys. Res. Commun. 404 2011 534 540
12. K. Maedler Beta cells in type 2 diabetes-a crucial contribution to pathogenesis Diabetes Obes. Metab. 10 2008 408 420
13. J.J. Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat. Rev. Endocrinol. 8 2012 728 742
14. D.E. Merry, and S.J. Korsmeyer Bcl-2 gene family in the nervous system Annu. Rev. Neurosci. 20 1997 245 267
15. M. Montminy Transcriptional regulation by cyclic AMP Annu. Rev. Biochem. 66 1997 807 822
16. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice Eur. J. Pharmacol. 588 2008 325 332
17. Y. Moritoh, K. Takeuchi, T. Asakawa, O. Kataoka, and H. Odaka Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice Br. J. Pharmacol. 157 2009 415 426
18. M.A. Nauck, I. Vardarli, C.F. Deacon, J.J. Holst, and J.J. Meier Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54 2011 10 18
19. S. Pugazhenthi, T. Boras, D. O'Connor, M.K. Meintzer, K.A. Heidenreich, and J.E. Reusch Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated pathway J. Biol. Chem. 274 1999 2829 2837
20. S. Pugazhenthi, E. Miller, C. Sable, P. Young, K.A. Heidenreich, L.M. Boxer, and J.E.-B. Reusch Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element binding protein J. Biol. Chem. 274 1999 27529 27535
21. S. Pugazhenthi, A. Nesterova, C. Sable, K. Heidenreich, L. Boxer, L. Heasley, and J. Reusch Akt/Protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein J. Biol. Chem. 275 2000 10761 10766
22. C.J. Rhodes Type 2 diabetes-a matter of beta-cell life and death? Science 307 2005 380 384
23. S.A. Sarkar, J. Gunter, R. Bouchard, J.E. Reusch, A. Wiseman, R.G. Gill, J.C. Hutton, and S. Pugazhenthi Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets Diabetologia 50 2007 1649 1659
24. A.J. Shaywitz, and M.E. Greenberg CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals Annu. Rev. Biochem. 68 1999 821 861
25. K. Velmurugan, A.N. Balamurugan, G. Loganathan, A. Ahmad, B.J. Hering, and S. Pugazhenthi Antiapoptotic actions of exendin-4 against hypoxia and cytokines are augmented by CREB Endocrinology 2012 1116 1128
26. J.R. White Alogliptin for the treatment of type 2 diabetes Drugs Today (Barc) 47 2011 99 107
27. X. Zhang, Z. Wang, Y. Huang, and J. Wang Effects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic mice Diabetes Obes. Metab. 13 2011 337 347